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mental antigens, characterized by a Th2/IgE-dominated inflammation. They can manifest themselves
in various organs, such as skin, gastrointestinal and respiratory tract, and comprise diseases as diverse
as allergic rhinitis and conjunctivitis, bronchial asthma, oral allergy syndrome, food allergy, urticaria
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increase in allergy prevalence, which has been mostly attributed to changes in environment and lifestyle.
But which, among all factors discussed, are the most relevant, and what are the mechanisms by which
these factors promote or prevent the development of allergic diseases? To answer this, it is necessary
to go back to the two key questions that have occupied allergy researchers for the last decades: Firstly,
what makes an allergen an allergen? Secondly, why are more and more individuals affected? Within
the last decade, we have made considerable progress in answering these questions. This review gives an
overview over scientific progress in the field, summarizes latest findings and points out future prospective
and research needs.
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Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): 
Change management in allergic rhinitis and asthma 
multimorbidity using mobile technology 
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Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from 
a guideline by using the best approach to integrated care pathways 
using mobile technology in patients with allergic rhinitis (AR) and 
asthma multimorbidity. The proposed next phase of ARIA is change 
management, with the aim of providing an active and healthy life to 
patients with rhinitis and to those with asthma multimorbidity across 
the lifecycle 
 
irrespective of their sex or socioeconomic status to reduce health and 
social inequities incurred by the disease. ARIA has followed the 8-
step model of Kotter to assess and implement the effect of rhinitis on 
asthma multimorbidity and to propose multimorbid guidelines. A 
second change management strategy is proposed by ARIA Phase 4 
to increase self-medication and shared decision making in rhinitis 
and asthma multimorbidity. An 
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innovation of ARIA has been the development and validation of 
information technology evidence-based tools (Mobile Airways 
Sentinel Network [MASK]) that can inform patient decisions on the 
basis of a self-care plan proposed by the health care professional. (J 
Allergy Clin Immunol 2018;nnn:nnn-nnn.) 
Key words: Change management, rhinitis, asthma, Allergic Rhinitis 
and Its Impact on Asthma 
Allergic Rhinitisand itsImpact onAsthma (ARIA) has evolved 
from a guideline using the best approach1-5 to integrated care 
pathways (ICPs) using mobile technology in patients with AR 
and asthma multimorbidity.6 The term comorbidity is commonly 
used for allergic diseases, but multimorbidity might be more 
appropriate. Comorbidity is the presence of 1 or more additional 
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diseases co-occurring with a primary disease or the effect of such 
additional disorders or diseases. Multimorbidity is a term that 
means co-occurring diseases in the same patient.7,8 
ARIA provides an evidence-based approach for managing the 
patient’s needs, but real-life data have shown that few patients use 
guidelines and that they often self-medicate (Menditto, in 
preparation). Moreover, patients largely use over-the-counter 
medications dispensed in pharmacies.9-11 Self-care and shared 
decision making (SDM) centered around the patient should be 
used more frequently. 
Change is inevitable in health care. ARIA has followed a 
change management (CM) strategy in the past, but a new revised 
plan should be considered to fill in the gaps of knowledge 
translation in practice and to increase the benefits of self-care in 
integrated care pathways (ICPs) by using the currently available 
information and communication technology tools.12 These 
changes should prepare and support individuals, teams, and 
organizations in making organizational change centered around 
the patient for more efficient care. 
BACKGROUND 
The 4 ARIA phases 
ARIA was initiated during a World Health Organization 
workshop in 19992 and has evolved in 4 phases. 
Phase 1 included development of an evidence-based document 
to provide a guide for the diagnosis and management of AR and 
asthma multimorbidity.1,2 In 2008, ARIA was updated using the 
same recommendation system.1,13 ARIA has been disseminated 
and is implemented in more than 70 countries around theworld.14 
For Phase 2, in its 2010 revision, ARIA was the first chronic 
respiratory disease guideline to adopt the Grading of 
Recommendation, Assessment, Development and Evaluation 
(GRADE) approach, an advanced evidence evaluation and 
recommendation methodology for guidelines.3,5 When guidelines 
are made using the same methodology, the recommendations are 
similar.5,15 
In Phase 3 ARIA focused on the implementation of emerging 
technologies for individualized and predictive medicine to 
develop ICPs for the management of AR and asthma by a 
multidisciplinary group centered around the patients (Mobile 
Airways Sentinel Network [MASK]).16-23 
The proposed ARIA Phase 4 is CM to provide an active and 
healthy lifestyle to patients with rhinitis and asthma across the 
lifecycle, irrespective of their sex or socioeconomic status, with 
the aim of reducing health and social inequities globally. 
SDM and patient empowerment 
In SDM both the patient and physician contribute to the medical 
decision-making process, placing the patient at the center of the 
decision-making paradigm.24 Physicians explain treatments and 
alternatives to patients, who then choose the treatment option that 
best aligns with their beliefs, lifestyles, and goals along with the 
benefits and risks.25 In contrast to SDM, the traditional medical 
care system places physicians in a position of authority, with 
patients playing a passive role in care. Patients want greater 
involvement in SDM.26 An innovation of SDM in ARIA is the use 
of information technology (IT) evidence-based tools that can 
 
inform patients’ decisions based on a guided selfmanagement plan 
proposed by their health care professionals.27 In asthmatic patients 
the effectiveness of 4 SDM studies shows improvement of control 
and some other parameters, but more studies are needed to 
confirm the data.28 
CM 
Change is inevitable in health care. However, many change 
projects fail because of varied beliefs and cultural circumstances, 
poor planning, unmotivated staff, deficient communication, or 
excessively frequent changes.29 
CM aims to prepare and support individuals, teams, and 
organizations in making organizational change. It proposes 
methods for redirecting or redefining resources, business 
processes, budget allocation, and/or modes of operation. When 
properly applied, CM significantly changes health care and its 
organization. However, health systems differ largely between 
countries or even regions, and a combination of CM with ICPs 
might be more relevant, allowing each organization to use the 
CM principlesaccordingtotheirneeds 
andregulations.CMdealswith different disciplines from health 
care, behavioral, and social sciences to IT and business solutions. 
Although theories might seem abstract and impractical for 
health care practice, they can help in planning solutions to 
common health care problems.29 The Lewin 3-step model is 
widely used30,31: unfreezing, moving, and refreezing.31 Lippitt et 
al32 and Kotter12 have added intermediate steps 
(Table I).12,29,31-33 
Several models of organizational and personal change have 
been reviewed for respiratory diseases.34 Kotter’s theory has been 
applied to different fields of medicine35-37 and pharmacies.38 
ARIA PHASES 1 AND 2 FOLLOWED THE KOTTER 
8-STEP CHANGE MODEL 
Goals 
Guidelines, such as Global Initiative for Asthma (GINA),39,40 
Global Initiative for Lung Diseases,41,42 EPOS (European 
Position Paper on Rhinosinusitis and nasal polyps),43 and 
ARIA,2,3,13 developed a CM strategy that was very effective and 
produced many updates and revisions while having a positive 
effect on clinical care and influencing research priorities. 
Most guidelines are condition specific, but ARIA was unique 
because it included, for the first time, the multimorbid 
component of airway diseases. Although it followed the patient’s 
perspectives, epidemiologic evidence,44 and some supporting 
mechanistic studies,45 this concept was not accepted by the 
leadership of GINA, who considered neither the asthma-rhinitis 
multimorbidity concept nor the benefit for the patients. 
The 8-step model 
Establish a sense of urgency. The sense of urgency should 
identify and highlight the potential threats and repercussions that 
might arise in the future by examining the opportunities thatcan 
be tapped througheffective interventions. Inpatients with AR and 
asthma, in the 1990s, the sense of urgency was to provide 
guidelines thatcould reduce both the burden ofthe disease and the 
mortality (in asthmatic patients). Although there were articles 
indicating the links between the upper and lower airways,46,47 the 
effect of rhinitis on asthma was not fully recognized, and ARIA 
was initiated to better recognize the interrelationships between 
the 2 diseases and to propose multimorbid guidelines. 
  
Development of Allergy; T2, type 2 immunity. 
Create a guiding coalition. The ARIAWorking Group was 
initiated during a World Health Organization meeting 
(December 1999) and evolved as a powerful group with 400 
members in 70 countries.14 Members have been working together 
for years and include all stakeholders needed for CM.1,6 The 
patient organization European Federation of Allergy and 
Airways Diseases Patients’ Associations has always been an 
active member of ARIA. Develop a vision and strategy. The 
ARIA vision has always been to provide a guide for the diagnosis 
and management of AR and asthma multimorbidity, including 
developing countries,1,2 by using the best available evidence.3,5 
ARIA has established 2 major targets: the recognition and 
implementation of the asthma-rhinitis multimorbidity, as well as 
a new classification (intermittent-persistent and mild-to-
moderate severe AR) to meet patients’ expectations. Moreover, 
ARIA priorities have always included primary care physicians, 
pharmacists, and patients’ organizations. 
Communicate the change vision. One of the ARIA strengths 
has been to communicate its vision effectively worldwide. More 
than 1000 articles have been posted on PubMed from more than 
50 countries by using the ARIA recommendations.14 The number 
of training sessions in more than 70 countries cannot be counted. 
ARIA has been endorsed by many governments and international 
organizations: ARIA recommendations have been used for the 
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TABLE I. Examples of planned change management models 
 BOUSQUET ET AL 5 
Lewin33 Kotter12  Lippitt et al32 
Unfreezing  Step 1: Establish a sense of urgency 
Step 2: Create a guiding coalition 
Step 3: Develop a vision and strategy 
 Phase 1: Diagnose the problem 
Phase 2: Assess motivation and capacity for change 
Phase 3: Assess change agent’s motivation and resources 
Moving Step 4: Communicate the change vision 
Step 5: Empower others to act on the vision 
Step 6: Generate short-term wins 
Step 7: Consolidate gains and produce more change 
 Phase 4: Select a progressive change objective 
Phase 5: Choose appropriate role of the change agent 
Refreezing  Step 8: Anchor new approaches in the culture and 
institutionalize the changes  
Phase 6: Terminate the helping relationship 
 
Adapted from Antwi et al.31 
 
FIG 1. Change management strategy of ARIA Phases 1 and 2. BAMSE, Barn Allergi Milj. Stockholm Epidemiologi Projektet; 
EGEA, Epidemiological Study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness and Atopy; MAS, 
German Multicenter Allergy Study; MeDALL, Mechanisms of the 
 
labeling of allergen immunotherapy by the European Medicines 
Agency. 
Empower others to act on the vision. Organizational processes 
and structures are in place and are aligned with the overall 
organizational vision. However, a continuous check is needed for 
barriers and for people who are resisting change. We have 
implemented proactive actions to remove the obstacles involved 
in the process of change. 
ARIA has been recognized as the major rhinitis and asthma 
multimorbidity guideline for years in most countries, except for 
the United States and Japan. However, the recent US guidelines 
are using the evidence-based approach of ARIA (GRADE), and 
the recommendations are similar15,48,49 to those of ARIA.5 The 
recent Japanese guidelines for AR are also creating bridges with 
ARIA.50 
Generate short-term wins. As proposed by Kotter,12 creating 
short-term wins early in the change process instead of having a 
single long-term goal can produce a feeling of victory in the early 
stages of change, which will reinforce support for the strategy. 
The concept of asthma and rhinitis multimorbidity is now 
globally accepted in developed and developing countries.51 It is 
now recognized that multimorbidity is independent of 
IgEmediated allergy,8,52 and new phenotypes of severe airway 
disease havebeen identified. The implementation of the 
multimorbid concept in clinical practice has a direct benefit for 
the patient whose nasal symptoms are often more bothersome than 
asthma. 
Consolidate gains and produce more change. The goals of step 
712 are to achieve continuous improvement by analyzing the 
success stories individually and improving from those individual 
experiences. These goals are exactly those that have been 
followed by ARIA for the past 18 years. 
Anchor new approaches in the culture and institutionalize the 
changes. The goals of step 812 are met by the ARIA strategy: 
1. Discuss widely the successful stories related to 
changeinitiatives. 
2. Ensure that the change becomes an integral part of 
thepractice and is highly visible. 
3. Ensure that the support of both existing and new 
leaderscontinues to extend toward the change. 
Results, drawbacks, and solutions 
ARIA has fully achieved its goals following the 8-step Kotter 
model shown Fig 1. The outcome assessment can be measured in 
the following ways. 
1. By the numbers of citations of ARIA: ARIA 2001 has been 
cited 1750 times, ARIA 2008 has been cited more than 2300 
times (and is the only article on asthma cited >200 times a 
year), and ARIA 2010 has been cited 710 times. This 
initiative is far better cited than GINA. 
2. By the countries that have endorsed ARIA in their national 
allergy programs: Finland, Malaysia, the Philippines, 
Portugal, and Singapore. 
3. By the approval of treatments by agencies: The European 
Medicines Agency used the ARIA classification in the 
approval of Acarizax (mite sublingual immunotherapy). 
Some drawbacks have been pointed out in the Kotter change 
model.12 In particular, the model is essentially top-down and might 
discourage any scope for participation or cocreation. In ARIAwe 
considered that the first CM model was a great success but that its 
lifecycle had come to an end. It was then decided within the 
coalition to propose a new CM model based on patients’ needs 
and emerging technologies (second phase of change management 
[CM2] model). 
Because the Kotter model cannot be redesigned, we proposed 
a new maturity CM model based on the same Kotter 8-step 
change model.12 We used ARIA Phase 3 (care pathways for 
rhinitis and asthma multimorbidity using mobile technology)6 to 
better plan the second CM model (CM2 model) and make new 
assumptions using a patient-centered approach. 
THE ALLERGY DIARY STRENGTHENS CM 
MASK 
In 2012, the European Commission launched the European 
Innovation Partnership on Active and Healthy Ageing 
(Directorate General for Health and Food Safety [DG Sante] and 
Directorate General for Communications Networks, Content & 
Technology).53 The B3 Action Plan, which was devoted to 
innovative integrated care models for chronic diseases, selected 
integrated care pathways for airway diseases (AIRWAYS 
ICPs)54,55 with a lifecycle approach56 as the model of chronic 
diseases. An AIRWAYS ICPs Action Plan was devised,54 
implemented,55 and scaled up.57,58 AIRWAYS ICPs is a World 
Health Organization Global Alliance against Chronic 
Respiratory Diseases59 research demonstration project (Fig 2). 
MASK, ARIA Phase 3, is an AIRWAYS ICPs tool.6,60 It 
represents a good practice focusing on the implementation of 
multisectoral care pathways using emerging technologies with 
real-life data in rhinitis and asthma multimorbidity. MASK 
follows the Joint Action on Chronic Diseases and Promoting 
Healthy Ageing across the Life Cycle (2nd EU Health 
Programme 2008-2013)61 
recommendations for good practices.18 
MASK was initiated to reduce the global burden of rhinitis and 
asthma by giving the patient a simple tool to better prevent and 
manage respiratory allergic diseases. More specifically, MASK 
should help to (1) understand the disease mechanisms and effects 
of air pollution in patients with allergic diseases, (2) better 
appraise the burden incurred by medical needs but also indirect 
costs, (3) propose novel multidisciplinary care pathways 
integrating pollution and patients’ literacy, (4) improve work 
productivity, (5) propose the basis for a sentinel network at the 
European Union level for pollution and allergy, and (6) assess 
the societal implications of the project to reduce health and social 
inequalities globally. 
The Allergy Diary 
The mobile technology of MASK is the Allergy Diary, an app 
(Android and iOS) freely available for patients with AR and 
asthma in 23 countries (16 European Union countries, Argentina, 
Australia, Brazil, Canada, Mexico, Switzerland, and Turkey) and 
16 languages (translated and back-translated, culturally adapted, 
and legally compliant; Fig 3).6 Anonymized users fill in a simple 
  
questionnaire on asthma and rhinitis on registration and daily 
assess the effect of the disease by using a visual analog scale62 
for global allergy symptoms, rhinitis, conjunctivitis, asthma, and 
work. Moreover, a questionnaire is applied every week to assess 
disease effect on patients’ quality of life (EuroQol).21 
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FIG 2. Links between ARIA and MASK for change management. DigitalHealthEurope, Digital Transformation of Health in 
Europe (H2020); Euriphi, Better Health and Care, Economic Growth and Sustainable Health Systems (H2020); GA2LEN, Global 
Allergy and Asthma European Network (FP6); GARD, Global Alliance against Chronic Respiratory Diseases; Good Practice DG 
Sante, Good Practice on digitally enabled, integrated, person-centered care of the Directorate-General for Health and Food 
Safety (European Commission); MACVIA-LR, Contre les Maladies Chroniques pour un Vieillisement Actif (European 
Innovation Partnership on Active and Healthy Ageing); MeDALL, Mechanisms of the Development of Allergy (FP7); SPAL, EU 
Development and Structural Funds; Sunfrail and Twinning, Vigour (Evidence-Based Guidance to Scale-up Integrated Care in 
Europe, 3rd Health Programme); WHO CC, World Health Organization Collab- 
orating Center. 
Data of pilot studies in up to 17,000 users and more than 
95,000 days are available. The Allergy Diary has been 
validated19 and has shown that (1) totally anonymized 
geolocation can be used in 23 countries (in preparation); (2) data 
can be analyzed in 23 countries and 17 languages; (3) sleep, 
work productivity, and daily activities are impaired in patients 
with AR16,17; (4) daily work productivity is associated with AR 
severity16; (5) everyday use of medications can be monitored, 
proposing a novel assessment of treatment patterns20; (6) novel 
patterns of multimorbidity havebeenidentified22 
andconfirmedinepidemiologicstudies8,63; and (7) more than 70% 
of patients with AR self-medicate and are nonadherent to 
medications (Menditto, in preparation). 
The Allergy Diary (Technology Readiness Level 9) represents 
a validated mobile health tool for the management of AR. 
Asthma has also been monitored, but data have not yet been 
analyzed. Economic effects can be monitored by using work 
productivity. The results of the AllergyDiary havemade 
innovativeapproaches of AR possible and are directly 
strengthening CM strategies in ARIA. 
Transfer of Innovation of MASK 
A Transfer of Innovation (Twinning) project has been funded 
by the European Innovation Partnership on Active and Healthy 
Ageing by using MASK in 25 reference sites or regions across 
Europe, Argentina, Australia, Brazil, Colombia, and Mexico.64 
The number of countries is increasing, and MASK should be 
rapidly operative in the United States, China, India (in English 
only), and Japan. This will improve the understanding, 
assessment of burden, diagnosis, and management of rhinitis in 
old age by comparison with an adult population. Twinning has 
been tested in Germany (Region Kohln-Bonn) in a pilot study 
that has now been extended to the other German cities and 
countries of the Twinning project. 
Clinical decision support system 
Clinical decision support systems are software algorithms that 
advise health care providers on diagnosis and management based 
on the interaction of patient data and medical information. They 
should be based on the best evidence to aid patients and health 
care professionals to jointly determine treatment (SDM). In 
patients with AR, the MASK clinical decision support system is 
incorporated into a tablet interoperable with the Allergy Diary65 
for health care professionals (ARIA Allergy Diary 
Companion).6,50 This is based on an algorithm to aid clinicians to 
select pharmacotherapy for patients with AR and to stratify their 
disease severity.66 This approach will be adapted for the patient’s 
guided self-care in the context of SDM. 
 
Impact of Air Pollution on Asthma and Rhinitis 
Interactions between air pollution, sleep, and allergic diseases 
are clear but insufficiently understood. Impact of Air Pollution on 
Asthma and Rhinitis (POLLAR) is a new Horizon 2020 project of 
the European Institute of Innovation and Technology for Health 
that will embed environmental data into the Allergy Diary. 
POLLAR aims at combining emerging technologies (including 
the Allergy Diary, which is Technology Readiness Level 9, 
meaning that the system is proved in an operational environment) 
with machine learning to (1) understand the effects of air pollution 
in patients with AR and its effects on sleep, work, and asthma; (2) 
assess societal consequences shared with citizens and 
professionals; (3) propose preventive strategies, including a 
sentinel network; and (4) develop participative policies. 
ARIA PHASES 3 AND 4 DEPLOY A NOVEL KOTTER 
8-STEP CHANGE MODEL 
Goals 
Although the first CM model developed by the ARIA initiative 
was a great success, there are still unmet needs in the treatment of 
asthma and rhinitis multimorbidity. In ARIA Phase 4 we 
encourage the participation of all the stakeholders. 
The 8-step model 
Establish a sense of urgency. ICPs will include 
multidisciplinary structured care plans detailing the keysteps of 
patient care, including self-care, as proposed by AIRWAYS 
ICPs.54 GRADE-based guidelines for physicians are available for 
AR, and their recommendations are similar.3,5,15 However, they 
are based onthe assumption that patients regularlyuse their 
treatment and are not tested with real-life data. Unfortunately, 
adherence to treatment is very low, and real-life studies do not 
necessarily accord with all recommendations.20 New-generation 
guidelines embedding real-life data are being developed. 
Create a guiding coalition. The ARIA Working Group initiated 
in 1999 includes more than 500 members in 70 countries.14 A 
successful coalition working on CM2 has been identified within 
the group. 
The AIRWAYS ICPs coalition was established in 2014 and is 
part of the European Innovation Partnership on Active and 
Healthy Ageing (DG Sante and Directorate General for 
Communications Networks, Content & Technology).54 
Moreover, many national and European scientific societies (the 
European Academy of Allergy and Clinical Immunology, the 
European Respiratory Society, and the International Primary 
Care Respiratory Group), and other patients’ organization 
(European Lung Foundation and Asthma UK) have joined the 
coalition. It is a World Health Organization Global Alliance 
against Chronic Respiratory Diseases demonstration 
project.Finally,the transfer ofinnovation of ARIA has been 
carried out to the reference sites of the European Innovation 
Partnership on Active and Healthy Ageing.64 
This CM2 guiding coalition is already in place in the European 
Forum for Research and Education in Allergy and Airways 
Diseases (http://www.euforea.eu).67 
Develop a vision and strategy. Thevision of ARIA Phase 4 is 
to provide CM2 for AR and asthma multimorbidity to develop 
SDM with the ultimate goal of improving AR and asthma control 
while maintaining quality of life and reducing costs by using 
mobile technology and real-time data management to inform 
decisions. 
The strategy for realizing the changes is based on the 
patientcentered implementation of ICPs54 using IT solutions, 
such as the Allergy Diary.6 
 
FIG 3. Allergy Diary. GPDR, General Data Protection Regulation (https://www.eugdpr.org). 
 
Communicate the change vision. The updated vision (CM2) 
will use the experience of the first CM strategy. It has already 
been discussed among the ARIA CM coalition members, 
andthepresentarticleisthefirsttobepublished.However, ittakes 
time to address the concerns of all stakeholders, and articles 
published recently on the Allergy Diary might help to convince 
many. ARIA is involving a maximum number of people to 
deploy the CM vision. 
The integration of new paths of understanding health and 
change is a requirement for the strategy. The CM2 model clearly 
expands and strengthens the potential for actual change to occur 
and take hold in all kinds of organizations and institutions. 
Supplementary to the ambition of change in existingpractices 
and institutions, it is also important to consider the integration of 
other modes of communication and dissemination on the basis 
of healthy behavior. A central example is the general need to 
increase the level of health literacy in society. The general public 
should clearly not be perceived simply as patients waiting for 
something to happen. Theyshouldhave the ability to navigate and 
understand health messages, an essential tool for self-managing 
well-being, even before any actual condition or major challenge 
actually occurs. However, to do so, one must consider how to 
improve this health literacy by integrating it much better into the 
educational system and cultural settings to which it applies. This 
is a very long-term investment in self-care and prevention. A 
later target audiencewith a higher level of health literacy will 
naturally also ensure an easier adoption of subsequent health 
messages, possibly using information and communication 
technology.68 The basis for understanding is simply enhanced 
compared with the previous scenario. 
In a similar line of thinking, one could also consider a wider 
community-oriented approach to dissemination. This could also 
coversocial media and self-help groups because some of the 
latter patients would benefit not only from both personal 
previous experience and knowledge about these ailments but 
also from a supportive environment, which would be better able 
to support and help these citizens/friends/family members, 
regardless of age, in their attempt to adapt to new modes of 
behavior. This is a wider application of the CM2 model and 
should also be considered in our work to help patients and 
citizens. 
Empower others to act on the vision. Organizational processes 
and structures are in place and are aligned with the overall 
organizational vision. However, we need to continuously check 
for barriers and for those who are resistant to change and focus on 
the education of both physicians and patients on how to achieve 
the best outcomes of treatment. We are acting proactively to 
remove the obstacles involved in the process of change. 
Generate short-term wins. We propose to create new short-
term (eg, 12 months) and medium-term (eg, 24 months) targets. 
In 2018, a high-level meeting organized by POLLAR will 
approach the improvement in care pathway design to enhance 
patient participation, health literacy, and self-care through 
technology-assisted ‘‘patient activation.’’ In this meeting rhinitis 
and asthma multimorbidity will be used as a model of 
noncommunicable disease (Fig 4). Three major aspects of ICPs 
will be considered: self-care, pharmacy care, and next-generation 
guidelines in which the recommendations of the GRADE 
guidelines on AR5,15 will be tested in real life by using MASK. 
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FIG 4. Change management based on next-generation ICPs. 
 
Consolidate gains and produce more change. Most of thegoals 
oftheKotter changemodelstep712 havebeenmetbythe ARIA CM 
and will be further developed in CM2. 
CONCLUSIONS 
Forthepast 18years, ARIAhas had themajorgoal ofproviding a 
guide for the diagnosis and management of AR and asthma 
multimorbidity applicable to developing countries1,2 by using the 
best evidence.3-5 ARIA Phases 1 and 2 were developed in 
accordance to the Kotter 8-step change model and can be used as 
a model of CM in patients with chronic diseases. However, there 
 are still unmet needs for the management of rhinitis and asthma 
in real life. 
A second CM model has been proposed by ARIA Phases 3 and 
4. It was initiated by the development in 23 countries of an app 
that showed partly unexpected results. Patients with AR (and 
possibly with asthma) do not follow physicians’ advice: they 
selfmedicate. There is an urgent need to harness this information 
and to update our concept of treatment, as well as treatment 
adherence, by using mobile technology and care pathways. This 
is the goal of ARIA Phase 4 and the second wave of CM. 
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